ClinicalTrials.gg
CompletedNCT06503679Updated Jan 24, 2025

A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants

A Phase 1 interventional study of LY4100511 (DC-853) Dose 1 and LY4100511 (DC-853) Dose 2 in Healthy, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-24.

Sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company (part of Eli Lilly and Company) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of this study is to assess the safety and tolerability and pharmacokinetics of LY4100511 (DC-853) when administered alone or in the presence of cytochrome P450 substrates in healthy participants.

02

Conditions studied

  • Healthy

Keywords

  • LY4100511
  • DC-853
03

In context

Lead sponsor

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company is the lead sponsor of 10 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 4 (40%) have results posted.

First submitted after DICE Therapeutics, Inc. became part of Eli Lilly and Company.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females must be of
  • Males must agree to use
  • Have (BMI) between 18.0 and 32.0 kilogram/square meter (kg/m²), inclusive, and a body weight of greater than or equal to 50 kg.
  • In good health, as determined by no findings from medical history, 12-lead and vital signs measurements, and clincial laboratory evaluations (congentical nonhemolytic hyperbilirubinemia) at screening and check-in, and from the physical examination at check-in as assessed by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Have a 12-lead abnormality that, in the opinion of the investigator,

    • increases the risks associated with participating in the study
    • may confound ECG data analysis
    • a QTCF >450 msec for males, or >470 msec for females

      • short PR interval \<120 msec or PR interval >220 msec
      • second or third degree atrioventricular block
      • intraventricular conduction delay with QRS >120 msec
      • complete right bundle branch block
      • left bundle branch block, or
      • Wolff Parkinson-White syndrome.
  • Have had current or recent acute infection
  • Show evidence of active or latent tuberculosis (TB)
  • Had any surgical procedures within 12 weeks prior to screening or any planned surgical procedure scheduled to occur during the study.
  • Have a history or presence of multiple or severe allergies, or an anaphylactic reaction to prescription or non prescription drugs.
  • Are
  • Presence of active suicidal ideation or positive suicide behavior using baseline/screening version of the C-SSRS
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    LY4100511 Dose 1 + Midazolam + Repaglinide (Cohort 1)

    Participants will receive an oral dose 1 of LY4100511 and single dose of midazolam and repaglinide.

    Drug: LY4100511 (DC-853) Dose 1 · Drug: Midazolam · Drug: Repaglinide

  • Experimental
    LY4100511 Dose 2 + Midazolam + Repaglinide (Cohort 2)

    Participants will receive up to an oral dose 2 of LY4100511 and single dose of midazolam and repaglinide. Dosing will not proceed until a satisfactory review of the safety and tolerability data from lower dose level is performed.

    Drug: LY4100511 (DC-853) Dose 2 · Drug: Midazolam · Drug: Repaglinide

  • Experimental
    LY4100511 Dose 3 + Digoxin and Rosuvastatin (Cohort 3)

    Participants will recive an oral dose 3 of LY4100511 and single dose of digoxin and rosuvastatin.

    Drug: LY4100511 (DC-853) Dose 3 · Drug: Digoxin · Drug: Rosuvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC [0-∞]) of Midazolam, in the absence or presence of steady-state LY4100511

    Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose

  2. Pharmacokinetics (PK): Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC [0-∞]) of 1-Hydroxymidazolam, in the absence or presence of steady-state LY4100511

    Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose

  3. Pharmacokinetics (PK): Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC [0-∞]) of Repaglinide, in the absence or presence of steady-state LY4100511

    Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose

  4. Pharmacokinetics (PK): Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC [0-∞]) of Digoxin, in the absence or presence of steady-state LY4100511

    Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose

  5. PK: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC[0-tlast]) of Midazolam, in the absence or presence of steady-state LY4100511

    Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose

  6. PK: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC[0-tlast]) of 1-Hydroxymidazolam, in the absence or presence of steady-state LY4100511

    Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose

  7. PK: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC[0-tlast]) of Repaglinide,in the absence or presence of steady-state LY4100511

    Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose

  8. PK: Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC[0-tlast]) of Digoxin, in the absence or presence of steady-state LY4100511

    Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose

  9. PK: Maximum Observed Concentration (Cmax) of Midazolam, in the absence or presence of steady-state LY4100511

    Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose

  10. PK: Maximum Observed Concentration (Cmax) of 1-Hydroxymidazolam, in the absence or presence of steady-state LY4100511

    Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose

  11. PK: Maximum Observed Concentration (Cmax) of Repaglinide, in the absence or presence of steady-state LY4100511

    Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose

  12. PK: Maximum Observed Concentration (Cmax) of Digoxin, in the absence or presence of steady-state LY4100511

    Time frame: Day 1 and Day 9: Predose, Up to 48 Hours Post Dose

07

Study locations

1 site
  • Fortrea Clinical Research Unit
    Dallas, Texas 75247, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Dec 2024, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2024
First posted
Jul 16, 2024
StartActual
Jul 16, 2024
Primary completionActual
Dec 31, 2024
CompletionActual
Dec 31, 2024
Last update
Jan 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06503679
Responsible party
Sponsor
First posted
Jul 16, 2024
Start date
Jul 16, 2024
Primary completion
Dec 31, 2024
Completion
Dec 31, 2024
Last update
Jan 24, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Simepdekinra · Midazolam · Repaglinide

Start the discussion